CN113749967A - Peptide composition and application thereof - Google Patents
Peptide composition and application thereof Download PDFInfo
- Publication number
- CN113749967A CN113749967A CN202111142693.4A CN202111142693A CN113749967A CN 113749967 A CN113749967 A CN 113749967A CN 202111142693 A CN202111142693 A CN 202111142693A CN 113749967 A CN113749967 A CN 113749967A
- Authority
- CN
- China
- Prior art keywords
- parts
- palmitoyl
- peptide composition
- hydrolyzed
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 121
- 239000000203 mixture Substances 0.000 title claims abstract description 99
- 108010035532 Collagen Proteins 0.000 claims abstract description 71
- 102000008186 Collagen Human genes 0.000 claims abstract description 71
- 229920001436 collagen Polymers 0.000 claims abstract description 71
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 67
- 229920001184 polypeptide Polymers 0.000 claims abstract description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 29
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 claims abstract description 28
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 claims abstract description 28
- FGSPQNZCLMWQAS-GPXNEJASSA-N (2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FGSPQNZCLMWQAS-GPXNEJASSA-N 0.000 claims abstract description 25
- 229940117982 palmitoyl dipeptide-7 Drugs 0.000 claims abstract description 25
- 239000002904 solvent Substances 0.000 claims abstract description 13
- 238000005282 brightening Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 35
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 35
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical group CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 10
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 10
- 241000251468 Actinopterygii Species 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003906 humectant Substances 0.000 claims description 7
- 108010016626 Dipeptides Proteins 0.000 claims description 6
- 150000005846 sugar alcohols Polymers 0.000 claims description 6
- 229920005862 polyol Polymers 0.000 claims description 5
- 150000003077 polyols Chemical class 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 29
- 230000037303 wrinkles Effects 0.000 abstract description 16
- 238000013329 compounding Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 59
- 210000003491 skin Anatomy 0.000 description 39
- 208000037259 Amyloid Plaque Diseases 0.000 description 21
- 239000000523 sample Substances 0.000 description 19
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 11
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 8
- 230000002087 whitening effect Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 5
- 229960002216 methylparaben Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010040829 Skin discolouration Diseases 0.000 description 4
- 229960000271 arbutin Drugs 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- 229960000401 tranexamic acid Drugs 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- MXZROAOUCUVNHX-UHFFFAOYSA-N 2-Aminopropanol Chemical compound CCC(N)O MXZROAOUCUVNHX-UHFFFAOYSA-N 0.000 description 2
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- CAHKINHBCWCHCF-UHFFFAOYSA-N N-acetyltyrosine Chemical compound CC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 238000011120 smear test Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000005211 surface analysis Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 1
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241001180876 Saposhnikovia Species 0.000 description 1
- 241001180873 Saposhnikovia divaricata Species 0.000 description 1
- 244000288377 Saxifraga stolonifera Species 0.000 description 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000006302 Usnea Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 244000131415 Zanthoxylum piperitum Species 0.000 description 1
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- -1 licorice extract Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a peptide composition and application thereof, wherein the peptide composition comprises the following components in parts by weight: 0.2-4 parts of hydrolyzed collagen, 0.01-2 parts of palmitoyl polypeptide and 90-99 parts of solvent. The peptide composition prepared by compounding the hydrolyzed collagen and the palmitoyl polypeptide has the effects of removing wrinkles, lightening spots and brightening skin, and particularly, when the hydrolyzed pigskin collagen, the palmitoyl tripeptide-5 and the palmitoyl dipeptide-7 are combined, a more prominent effect of lightening the senile spots and brightening skin can be obtained.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a peptide composition and application thereof.
Background
The skin is used as the first barrier of human body, the skin is aged and aged all the time, the elasticity of the skin is slowly reduced, the skin becomes thinner, weaker and loose, and the visual impression of the skin is wrinkle and senile plaque. Skin aging is the prevention of gradual functional and organic degenerative changes in the skin over time, manifested by the prevention of wrinkles, dryness, scaling, sagging and discolorations. Anti-aging cosmetics are important functional cosmetics for realizing anti-aging effect.
The hydrolyzed collagen is prepared by a scientific processing method, can be completely dissolved in water relative to collagen polypeptide with small molecular weight, and has higher absorption and utilization rate by human bodies. The hydrolyzed collagen contains a plurality of amino acids, wherein the total amount of the amino acids is more than ninety percent of the hydrolyzed collagen by the maximum amount of the dry amino acids, and the secondary amino acids are alanine, glutamic acid, arginine, hydroxyproline and the like, and the content of the strong proline is up to 11.8-12.6 percent. These amino acids are important raw materials for the synthesis of autologous collagen by humans. Only when a human takes in enough amount of various amino acids, various proteins required by the human can be synthesized, the shape and structure of skin and tissues and organs are maintained, and various damaged tissues are repaired.
The polypeptide has various biological activities of scavenging free radicals, resisting oxidation, resisting aging and the like, can promote the proliferation of skin cells, can provide nutrition for skin, delays skin aging and promotes skin wound repair, and is widely applied to skin cosmetics and anti-aging cosmetics.
However, the efficacy of hydrolyzed collagen and polypeptides, particularly palmitoyl polypeptides, in lightening and removing freckles has not been described in the prior art. For example, patent document CN 109646324A describes a tightening and whitening spot-lightening cream extracted from collagen complex plant, which is prepared by mixing hydrolyzed collagen zinc, acetyl tyrosine, glutathione, alanine, valine, nicotinamide, squalane, xanthan gum, butylene glycol, carbomer, arbutin, citric acid, strawberry saxifrage extract, peony root extract, aminopropanol ascorbic acid phosphate, scutellaria membranaceus root extract, saposhnikovia divaricata root extract, rose oil, zanthoxylum piperitum fruit extract, usnea extract and deionized water. However, the skin can be moisturized and firmed by adding the collagen with small molecular weight, and the components with the effects of whitening and lightening the spots are acetyl-tyrosine, glutathione, arbutin, citric acid, a peony root extract, aminopropanol ascorbic acid phosphate and a divaricate saposhnikovia root extract. Patent document CN107714525A describes a specific essence for whitening and removing freckles, which includes metallothionein, tranexamic acid, hyaluronic acid, hydrolyzed collagen, top-level natural whitening moisturizing factors, amino acid moisturizers, licorice extract, olive oil, arbutin, lecithin wax, bitter orange flower essential oil, brown algae gel, and ceramide. However, the components which exert the whitening and spot-lightening effects are metallothionein, tranexamic acid, hyaluronic acid, liquorice extract and arbutin, and the spot-lightening effect of hydrolyzed collagen is not recorded. Patent document CN 109288753 a describes a whitening spot-lightening cream, which contains multiple oligopeptides, multiple plant extracts and a powerful humectant, and simultaneously, glabrous licorice anus and tranexamic acid, which are called whitening gold, are added to play a role in whitening and spot-lightening; the skin moisture can be supplemented, and the damaged skin can be repaired in time, so that the skin is white and red without stripes. As can be seen, although palmitoyl peptide is added in this document, the effect is only to reduce fine wrinkles, and the effects of spot lightening and spot removal, particularly the spot lightening effect for senile plaques, are not described.
Senile plaque is a skin degeneration of the elderly, and is represented by scattered pigmented plaque pieces which are different in size, flat or slightly higher than the skin surface, smooth in surface and tan in color. It is often seen in the exposed areas, such as the face, forehead, back of the hand, etc. The traditional method for removing senile plaque comprises CO2Laser, electric ion cauterization, freezing, grinding, surgical grafting, etc., but theseThe method is easy to produce adverse reactions such as scar and pigmentation. And the existing cosmetics are only rarely reported to the products for fading and removing the senile plaques, so that the research and development of the cosmetics with the obvious effects of fading and removing the senile plaques are urgently needed.
Disclosure of Invention
In view of the defects of the prior art, the invention aims to provide a peptide composition and application thereof, in particular to application of the peptide composition in preparing wrinkle-removing and/or spot-lightening skin-brightening products.
The purpose of the invention is realized by the following technical scheme:
in a first aspect, the invention provides a peptide composition, which comprises the following components in parts by weight: 0.2-4 parts of hydrolyzed collagen, 0.01-2 parts of palmitoyl polypeptide and 90-99 parts of solvent.
Preferably, the peptide composition comprises the following components in parts by weight: 1-1.5 parts of hydrolyzed collagen, 0.7-1.0 part of palmitoyl polypeptide and 95-98 parts of solvent.
Preferably, the palmitoyl polypeptide is at least one of palmitoyl dipeptide, palmitoyl tripeptide, palmitoyl pentapeptide, and palmitoyl hexapeptide.
Preferably, the palmitoyl polypeptide is palmitoyl tripeptide-5 or a mixture of palmitoyl tripeptide-5 and palmitoyl dipeptide-7.
Preferably, when the palmitoyl polypeptide is a mixture of palmitoyl tripeptide and palmitoyl dipeptide-7, the mixing weight ratio of the palmitoyl tripeptide and the palmitoyl dipeptide-7 is 6-8: 2-4.
Preferably, the hydrolyzed collagen is at least one of hydrolyzed fish collagen and hydrolyzed pig skin collagen. More preferably hydrolyzed pigskin collagen.
Preferably, the peptide composition also comprises 0.05 to 0.2 weight part of humectant; the humectant is selected from ethylhexyl glycerin;
the solvent is a mixture of water and polyhydric alcohol, and the mixing ratio of the water to the polyhydric alcohol is 70-90: 10-30;
the polyol is at least one selected from 1, 2-hexanediol and glycerol.
Preferably, the polyol is 1, 2-hexanediol. 1, 2-hexanediol has moisturizing and skin conditioning effects.
The peptide composition prepared by the invention has the effects of removing wrinkles, lightening spots and brightening skin, and particularly, when the combination of hydrolyzed pigskin collagen, palmitoyl tripeptide-5 and palmitoyl dipeptide-7 is adopted, more outstanding wrinkle removing effect and senile plaque lightening effect can be obtained.
In a second aspect, the invention provides an application of a peptide composition in preparing a spot-lightening and skin-brightening product, wherein the peptide composition comprises the following components in parts by weight: 0.2-4 parts of hydrolyzed collagen, 0.01-2 parts of palmitoyl polypeptide and 90-99 parts of solvent.
Preferably, the peptide composition comprises the following components in parts by weight: 1-1.5 parts of hydrolyzed collagen, 0.7-1.0 part of palmitoyl polypeptide and 95-98 parts of solvent.
Preferably, the palmitoyl polypeptide is at least one of palmitoyl dipeptide, palmitoyl tripeptide, palmitoyl pentapeptide, and palmitoyl hexapeptide.
Preferably, the palmitoyl polypeptide is palmitoyl tripeptide-5 or a mixture of palmitoyl tripeptide-5 and palmitoyl dipeptide-7.
Preferably, when the palmitoyl polypeptide is a mixture of palmitoyl tripeptide and palmitoyl dipeptide-7, the mixing weight ratio of the palmitoyl tripeptide and the palmitoyl dipeptide-7 is 6-8: 2-4.
Preferably, the hydrolyzed collagen is at least one of hydrolyzed fish collagen and hydrolyzed pig skin collagen. More preferably hydrolyzed pigskin collagen.
Preferably, the peptide composition also comprises 0.05 to 0.2 weight part of humectant; the humectant is selected from ethylhexyl glycerin;
the solvent is a mixture of water and polyhydric alcohol, and the mixing ratio of the water to the polyhydric alcohol is 70-90: 10-30;
the polyol is at least one selected from 1, 2-hexanediol and glycerol.
Preferably, the polyol is 1, 2-hexanediol. 1, 2-hexanediol has moisturizing and skin conditioning effects.
Preferably, the peptide composition is contained in the spot-lightening and skin-brightening product in an amount of 0.5-10%.
Preferably, the spot lightening and skin lightening product comprises an age spot lightening product and/or a skin lightening product.
In a third aspect, the invention also provides an application of the peptide composition in preparing a wrinkle-removing and/or speckle-lightening product, wherein the peptide composition comprises the following components in parts by weight: 0.2-4 parts of hydrolyzed collagen, 0.01-2 parts of palmitoyl polypeptide and 90-99 parts of solvent;
in the wrinkle-removing and/or speckle-lightening product, the content of the peptide composition is 0.5-10%.
Compared with the prior art, the invention has the following beneficial effects:
1. according to the invention, the hydrolyzed collagen and the palmitoyl polypeptide are compounded, so that the peptide composition prepared from the hydrolyzed collagen and the palmitoyl polypeptide has a good wrinkle removing effect, and also has the effects of spot lightening and skin brightening, and especially has an obvious effect of senile plaque lightening.
2. The invention further adopts the compounding of the palmitoyl tripeptide-5 and the palmitoyl dipeptide-7, combines the hydrolyzed pigskin collagen, and can further improve the wrinkle removing effect and remarkably improve the effects of senile plaque lightening and skin color brightening through the synergistic effect of the palmitoyl tripeptide-5 and the palmitoyl dipeptide-7.
Drawings
Other features, objects and advantages of the invention will become more apparent upon reading of the detailed description of non-limiting embodiments with reference to the following drawings:
FIG. 1 is a photograph showing a comparison of senile plaques of a subject before and after application of an experimental sample 2; wherein, FIG. 1a is a photograph before painting; FIG. 1b is a photograph after 8 weeks of application;
FIG. 2 is a photograph showing a comparison of senile plaques of a subject before and after applying the test sample 3; wherein, FIG. 2a is a photograph before painting; fig. 2b is a photograph after 8 weeks of application.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
Example 1
The embodiment provides a peptide composition, which comprises the following components in parts by weight: 2 parts of hydrolyzed fish collagen, 51 parts of palmitoyl tripeptide, 87 parts of water and 10 parts of 1, 2-hexanediol.
The peptide composition is prepared by the following steps:
1) uniformly mixing 10 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed fish collagen in 77 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B to obtain the clear and transparent peptide composition.
Example 2
The embodiment provides a peptide composition, which comprises the following components in parts by weight: 0.5 part of hydrolyzed fish collagen, 50.1 parts of palmitoyl tripeptide, 91.3 parts of water, 8 parts of 1, 2-hexanediol and 0.1 part of ethylhexyl glycerol.
The peptide composition is prepared by the following steps:
1) uniformly mixing 20 parts of water and 8 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed fish collagen in 71.3 parts of water to obtain a solution B;
3) and uniformly mixing the solution A and the solution B to obtain the clear and transparent peptide composition.
Example 3
The embodiment provides a peptide composition, which comprises the following components in parts by weight: hydrolyzed pigskin collagen 1 part, palmitoyl tripeptide-50.7 parts, palmitoyl dipeptide-70.3 parts, water 87.5 parts, 1, 2-hexanediol 10 parts, and ethylhexyl glycerin 0.5 part.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 and palmitoyl dipeptide-7 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 72.5 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Example 4
The embodiment provides a peptide composition, which comprises the following components in parts by weight: 1 part of hydrolyzed fish collagen, 50.7 parts of palmitoyl tripeptide, 70.3 parts of palmitoyl dipeptide, 87.5 parts of water, 10 parts of 1, 2-hexanediol and 0.5 part of ethylhexyl glycerol.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 and palmitoyl dipeptide-7 to obtain a clear and transparent solution A;
2) dissolving the hydrolyzed fish skin collagen in 72.5 parts of water to obtain a solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Example 5
The embodiment provides a peptide composition, which comprises the following components in parts by weight: hydrolyzed pigskin collagen 1 part, palmitoyl tripeptide-51 parts, water 87.5 parts, 1, 2-hexanediol 10 parts, and ethylhexyl glycerin 0.5 part.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 72.5 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Example 6
The embodiment provides a peptide composition, which comprises the following components in parts by weight: hydrolyzed pigskin collagen 1 part, palmitoyl tripeptide-50.5 parts, palmitoyl dipeptide-70.5 parts, water 87.5 parts, 1, 2-hexanediol 10 parts, and ethylhexyl glycerin 0.5 part.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 and palmitoyl dipeptide-7 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 72.5 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Example 7
The embodiment provides a peptide composition, which comprises the following components in parts by weight: hydrolyzed pigskin collagen 1 part, palmitoyl tripeptide-50.7 parts, palmitoyl pentapeptide-40.3 parts, water 87.5 parts, 1, 2-hexanediol 10 parts, and ethylhexyl glycerol 0.5 part.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 and palmitoyl pentapeptide-4 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 72.5 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Example 8
The embodiment provides a peptide composition, which comprises the following components in parts by weight: hydrolyzed pigskin collagen 1.5 parts, palmitoyl tripeptide-50.5 parts, palmitoyl dipeptide-70.2 parts, water 87.5 parts, 1, 2-hexanediol 10 parts, and ethylhexyl glycerin 0.5 part.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 and palmitoyl dipeptide-7 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 72.5 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Example 9
The embodiment provides a peptide composition, which comprises the following components in parts by weight: hydrolyzed pigskin collagen 1.2 parts, palmitoyl tripeptide-50.6 parts, palmitoyl dipeptide-70.4 parts, water 87.3 parts, 1, 2-hexanediol 10 parts, and ethylhexyl glycerin 0.5 part.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 and palmitoyl dipeptide-7 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 72.3 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Example 10
The embodiment provides a peptide composition, which comprises the following components in parts by weight: 0.5 part of hydrolyzed pigskin collagen, 50.7 parts of palmitoyl tripeptide, 70.3 parts of palmitoyl dipeptide, 88 parts of water, 10 parts of 1, 2-hexanediol and 0.5 part of ethylhexyl glycerol.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 and palmitoyl dipeptide-7 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 73 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Example 11
The embodiment provides a peptide composition, which comprises the following components in parts by weight: hydrolyzed pigskin collagen 1 part, palmitoyl tripeptide-50.35 parts, palmitoyl dipeptide-70.15 parts, water 88 parts, 1, 2-hexanediol 10 parts, and ethylhexyl glycerin 0.5 part.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 and palmitoyl dipeptide-7 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 73 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Example 12
The embodiment provides a peptide composition, which comprises the following components in parts by weight: 1 part of hydrolyzed pigskin collagen, 71 parts of palmitoyl dipeptide, 88 parts of water, 10 parts of 1, 2-hexanediol and 0.5 part of ethylhexyl glycerol.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-1 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 73 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Comparative example 1
The comparative example provides a peptide composition comprising the following components in parts by weight: hydrolyzed pigskin collagen 1 part, palmitoyl tripeptide-10.7 parts, palmitoyl dipeptide-70.3 parts, water 87.5 parts, 1, 2-hexanediol 10 parts, and ethylhexyl glycerin 0.5 part.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-1 and palmitoyl dipeptide-7 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 72.5 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Comparative example 2
The comparative example provides a peptide composition comprising the following components in parts by weight: hydrolyzed pigskin collagen 1 part, palmitoyl tripeptide-50.7 parts, palmitoyl tetrapeptide-70.3 parts, water 87.5 parts, 1, 2-hexanediol 10 parts, and ethylhexyl glycerol 0.5 part.
The peptide composition is prepared by the following steps:
1) uniformly mixing 15 parts of water and 10 parts of 1, 2-hexanediol, and adding palmitoyl tripeptide-5 and palmitoyl tetrapeptide-7 to obtain a clear and transparent solution A;
2) dissolving hydrolyzed pigskin collagen in 72.5 parts of water to obtain solution B;
3) and uniformly mixing the solution A and the solution B, and then adding ethylhexyl glycerol and mixing to obtain the clear and transparent peptide composition.
Effect verification:
1. wrinkle removing effect
The experimental method comprises the following steps:
selecting the left and right canthus parts, and performing by an instrument evaluation method. The age of the testees is 25-50 years, the number of the testees is 60, and the testees are divided into 6 groups on average. The face is cleaned on the test day, the moisture is absorbed by paper towels, and the face is dried and balanced for 20-30 min in a constant temperature and humidity chamber (the temperature is 20 +/-2 ℃ and the relative humidity is 30% -60%). The positions of the left and right canthi are marked, and the canthus wrinkles before use are photographed and analyzed by using a skin microscope VC98 and an active skin surface analysis system SELS.
Using samples after cleaning every morning and evening, the left canthus of 6 groups of subjects were smeared with experimental samples 1-6 (sample matrix comprising 0.3% U21, 0.3% methyl paraben, 0.3% triethanolamine, balance water) containing the peptide compositions prepared in example 2, example 3, example 5, example 12, comparative example 1, comparative example 2 at a concentration of 5%, respectively, and the right canthus of two groups of subjects were smeared with a matrix control sample containing no peptide composition, each time the size of mung bean was evenly smeared in the test area and kept dry. After 2, 4, 6, 8 weeks of use, the test day after the cleaning balance the control pre-use area was again photographed using the skin microscope VC98 and the active skin surface analysis system SELS for the corner wrinkles and analyzed for changes in SEw.
The experimental results are as follows:
the effect of experimental samples 1 and 2 on skin wrinkles was calculated by calculating the stroma control test value at each time point as 100% based on the test value before use. Significant differences were calculated with the method of TTest after use compared to before use, P <0.05, P < 0.01. The calculation formula is as follows:
a) the change rate%
b) Relative change% (% change in sample group/change in matrix group × 100%)
The evaluation results of skin wrinkles SEw using VC98 are shown in table 1 (results are average values). The experimental sample containing 5% peptide composition began to decrease in skin wrinkle parameter SEw 2 weeks after use, with a significant difference after 6 weeks of use, compared to before use (time 0 weeks). After 8 weeks of continuous use, the skin wrinkles are obviously reduced, and the reduction rate can reach 80.2% at least. Thus, it was demonstrated that skin wrinkles can be improved by using a peptide composition containing 5% of the peptide of the present invention for a long period of time.
TABLE 1
2. Speckle reducing effect
The experimental method comprises the following steps:
subjects aged 55-75 years and having obvious senile plaques were randomly divided into 15 groups of 5 persons each. Subjects applied each day after cleansing their face in the morning and evening the area size of the senile plaques in the test area after applying each of the experimental samples 1-12 (sequentially corresponding to 5% of the peptide composition prepared in examples 1-12, using a sample matrix comprising 0.3% U21, 0.3% methyl paraben, 0.3% triethanolamine, and the balance water) and the comparative samples 1-2 (sequentially corresponding to 5% of the peptide composition prepared in comparative examples 1-2, using a sample matrix comprising 0.3% U21, 0.3% methyl paraben, 0.3% triethanolamine, and the balance water) to the test area, continuously for 8 weeks, before application and after applying the experimental samples for 2, 4 and 8 weeks. And the same test was performed using the sample matrix without the peptide composition as a control sample.
The experimental results are as follows:
calculating the change rate (%) of the area of the senile plaque according to the change of the area of the senile plaque before and after use, wherein the calculation formula is as follows:
senile plaque area change rate (%) gamma 100%
The results obtained are shown in table 2 (average values), and the peptide composition prepared by hydrolyzing collagen and palmitoyl tripeptide-5 or palmitoyl dipeptide-7 (sample 1/2/12) has a certain senile plaque-lightening effect; when the palmitoyl tripeptide-5 and palmitoyl dipeptide-7 are compounded, the senile plaque lightening effect of the prepared peptide composition is obviously improved; particularly, when the hydrolyzed pigskin collagen with specific content and the palmitoyl tripeptide-5 and the palmitoyl dipeptide-7 with specific proportion are adopted, the effect of remarkably lightening the senile plaques can be obtained. While there was little or no effect of lightening age spots when compounded with other types of palmitoyl polypeptides (comparative examples 1 and 2). Therefore, the invention can obtain very obvious spot-lightening effect through the coordination of the selection of specific palmitoyl polypeptide types and the compounding of the palmitoyl polypeptide types and hydrolyzed collagen, particularly hydrolyzed pigskin collagen.
FIG. 1 is a photograph showing a comparison of senile plaques of one subject before and after application of the test sample 2. Fig. 2 is a photograph showing a comparison of senile plaques of one subject before and after application of the experimental sample 3. As can be seen from fig. 1 and 2, the effect of lightening age spots of the smear test sample 3 is significantly better than that of the smear test sample 2.
TABLE 2
3. Skin lightening effect
The experimental method comprises the following steps:
subjects aged 25-50 years were randomized into 15 groups of 5 individuals each. Subjects applied each test sample 1-12 (sequentially containing 5% of the peptide composition prepared in examples 1-12, a sample base comprising 0.3% U21, 0.3% methyl paraben, 0.3% triethanolamine, and the balance water) and comparative sample 1-2 (sequentially containing 5% of the peptide composition prepared in comparative examples 1-2, a sample base comprising 0.3% U21, 0.3% methyl paraben, 0.3% triethanolamine, and the balance water) to the subject site after daily cleansing of the face in the morning and evening, for 8 weeks, and skin color was measured 2, 4, and 8 weeks before application (0 weeks) and after application with the test samples. And the same test was performed using the sample matrix without the peptide composition as a control sample.
Skin chromaticity values of L, a, b of the skin at the test site were measured separately using a skin colorimeter, three times for each test area, and the ITA ° values were recorded and calculated. The larger the ITA DEG value of the tested skin area, the lighter the skin color and vice versa.
The experimental results are as follows:
the results are shown in table 3, and the peptide composition prepared by the invention has obvious skin lightening effect. Particularly, when the palmitoyl tripeptide-5 and palmitoyl dipeptide-7 are compounded with hydrolyzed collagen, the skin color can be remarkably lightened through the coordination effect of the palmitoyl tripeptide-5 and the palmitoyl dipeptide-7.
TABLE 3
4. Safety test
The experimental method comprises the following steps:
this experiment researchThe safety of each peptide composition was evaluated by examining the toxicity of the peptide composition obtained in each example to human primary fibroblast NHF cells after the peptide composition acted on the cells. Taking NHF cells growing in logarithmic phase, discarding culture solution, washing with PBS for 2 times, adding 0.05% pancreatin, standing at 37 deg.C for 5min, stopping digestion with DMEM complete culture solution containing 10% FBS and 1% PS, collecting cells, centrifuging at 1000rpm for 3min, discarding supernatant, resuspending cells with complete culture solution, counting, and adjusting cell concentration to 1 × 105Each well was 100. mu.l/ml in a 96-well plate. After 24h, the cells are attached, and 100. mu.l of the test sample with the peptide composition concentration ranging from 1% to 10% after dilution is added to each well. Mixing, and further incubating in the incubator for 24 + -1 h.
The experimental results are as follows: the peptide composition prepared in all the examples has no obvious toxicity to cells and no safety problem at the concentration of 1-10%.
The invention has many applications, and the above description is only a preferred embodiment of the invention. It should be noted that the above examples are only for illustrating the present invention, and are not intended to limit the scope of the present invention. It will be apparent to those skilled in the art that various modifications can be made without departing from the principles of the invention and these modifications are to be considered within the scope of the invention.
Claims (10)
1. The peptide composition is characterized by comprising the following components in parts by weight: 0.2-4 parts of hydrolyzed collagen, 0.01-2 parts of palmitoyl polypeptide and 90-99 parts of solvent.
2. The application of a peptide composition in preparing a spot-lightening skin-brightening product is characterized in that the peptide composition comprises the following components in parts by weight: 0.2-4 parts of hydrolyzed collagen, 0.01-2 parts of palmitoyl polypeptide and 90-99 parts of solvent.
3. The use according to claim 2, wherein the peptide composition comprises the following components in parts by weight: 1-1.5 parts of hydrolyzed collagen, 0.7-1.0 part of palmitoyl polypeptide and 95-98 parts of solvent.
4. The use of claim 2, wherein the palmitoyl polypeptide is at least one of palmitoyl dipeptide, palmitoyl tripeptide, palmitoyl pentapeptide, and palmitoyl hexapeptide.
5. Use according to claim 2, wherein the palmitoyl polypeptide is palmitoyl tripeptide-5 or a mixture of palmitoyl tripeptide-5 and palmitoyl dipeptide-7.
6. The use of claim 5, wherein the palmitoyl polypeptide is a mixture of palmitoyl tripeptide-5 and palmitoyl dipeptide-7 in a weight ratio of 6-8: 2-4.
7. The use of claim 2, wherein the hydrolyzed collagen is at least one of hydrolyzed fish collagen and hydrolyzed porcine skin collagen.
8. The use according to claim 2, wherein the peptide composition further comprises from 0.05 to 0.2 parts by weight of a humectant; the humectant is selected from ethylhexyl glycerin;
the solvent is a mixture of water and polyhydric alcohol, and the mixing ratio of the water to the polyhydric alcohol is 70-90: 10-30;
the polyol is at least one selected from 1, 2-hexanediol and glycerol.
9. The use according to claim 2, wherein the peptide composition is present in the spot-lightening product in an amount of from 0.5% to 10%.
10. The application of a peptide composition in preparing a wrinkle-removing and/or speckle-lightening product is characterized in that the peptide composition comprises the following components in parts by weight: 0.2-4 parts of hydrolyzed collagen, 0.01-2 parts of palmitoyl polypeptide and 90-99 parts of solvent;
in the wrinkle-removing and/or speckle-lightening product, the content of the peptide composition is 0.5-10%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111142693.4A CN113749967B (en) | 2021-09-28 | 2021-09-28 | Peptide composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111142693.4A CN113749967B (en) | 2021-09-28 | 2021-09-28 | Peptide composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113749967A true CN113749967A (en) | 2021-12-07 |
| CN113749967B CN113749967B (en) | 2023-07-14 |
Family
ID=78798025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111142693.4A Active CN113749967B (en) | 2021-09-28 | 2021-09-28 | Peptide composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113749967B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115487125A (en) * | 2022-01-28 | 2022-12-20 | 山西海博贝马生物科技有限公司 | Bactericidal composition and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406556A (en) * | 2011-11-16 | 2012-04-11 | 无限极（中国）有限公司 | Cosmetic composition favorable for keeping biological activity of epidermal growth factor (EGF) |
| CN109864899A (en) * | 2019-03-05 | 2019-06-11 | 上海珈凯生物科技有限公司 | A kind of peptides composition with delay skin aging and preparation method thereof, application |
| CN111249215A (en) * | 2020-02-28 | 2020-06-09 | 广东肽世家生物科技有限公司 | Multi-effect whitening and freckle-removing cream and preparation method thereof |
-
2021
- 2021-09-28 CN CN202111142693.4A patent/CN113749967B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406556A (en) * | 2011-11-16 | 2012-04-11 | 无限极（中国）有限公司 | Cosmetic composition favorable for keeping biological activity of epidermal growth factor (EGF) |
| CN109864899A (en) * | 2019-03-05 | 2019-06-11 | 上海珈凯生物科技有限公司 | A kind of peptides composition with delay skin aging and preparation method thereof, application |
| CN111249215A (en) * | 2020-02-28 | 2020-06-09 | 广东肽世家生物科技有限公司 | Multi-effect whitening and freckle-removing cream and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 周春霞 等: "棕榈酰寡肽组合物延缓皮肤衰老的功效研究", 《日用化学工业》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115487125A (en) * | 2022-01-28 | 2022-12-20 | 山西海博贝马生物科技有限公司 | Bactericidal composition and application thereof |
| CN115487125B (en) * | 2022-01-28 | 2023-09-12 | 山西海博贝马生物科技有限公司 | Sterilization composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113749967B (en) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10231917B2 (en) | Pro-pigmenting peptides | |
| EP3468983B1 (en) | Peptide, composition comprising said peptide and uses thereof, in particular cosmetic uses | |
| JP7285848B2 (en) | Use of cyclic peptides in cosmetics | |
| CN104203210B (en) | The cosmetic applications of albizzia julibrissin extract and corresponding local composite | |
| CN108852894A (en) | It is a kind of for repairing the polypeptides in combination of whitening wrinkle-removing | |
| KR20100025500A (en) | Composition for improving beauty of skin containing collagen peptide | |
| SG190342A1 (en) | Cosmetic composition for whitening and improving the resilience of skin | |
| EP2914349B1 (en) | Combination of plant extracts, cosmetic ingredient and composition containing it and topical cosmetic use thereof | |
| CN107365355B (en) | Anti-wrinkle peptide and cosmetic comprising same | |
| CN113749967B (en) | Peptide composition and application thereof | |
| EP3773460B1 (en) | Use of a peptide for the treatment of epiderm | |
| CN115463051A (en) | Whitening essence for sensitive skin and preparation method thereof | |
| JP2012232915A (en) | Skin care preparation for antiaging | |
| CN111557872A (en) | Skin care product of multi-oligopeptide composition | |
| KR102281606B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex | |
| CN115869230A (en) | Anti-wrinkle cosmetic and preparation method thereof | |
| CN111961119B (en) | Application of polypeptide in preparation of medicine or cosmetic for promoting collagen secretion | |
| CN111888279B (en) | Method for promoting collagen production and corresponding medicine or cosmetic | |
| CN107400160B (en) | Anti-relaxing, anti-firming peptides and cosmetic products containing the same | |
| CN114555045A (en) | Peptide-based cosmetic or dermatological treatment of skin and its appendages | |
| WO2020165365A1 (en) | Active ingredient for homogenizing complexion, in particular skins with an olive carnation | |
| CN112294683A (en) | Cosmetic with epidermis moisturizing and skin anti-wrinkle effects and preparation and application thereof | |
| KR102382002B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex and natural ingredients | |
| KR20190037094A (en) | Skin external composition for promoting skin keratin turnover | |
| CN117598924A (en) | Plant polypeptide composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 201500 building 6, No. 857, Tiangong Road, Jinshan District, Shanghai Applicant after: Shanghai Jiakai Biological Co.,Ltd. Address before: 201500 building 6, No. 857, Tiangong Road, Jinshan District, Shanghai Applicant before: SHANGHAI JIAKAI BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: No. 818 Tiangong Road, Jinshan District, Shanghai, 200540 Patentee after: Shanghai Jiakai Biological Co.,Ltd. Address before: 201500 building 6, No. 857, Tiangong Road, Jinshan District, Shanghai Patentee before: Shanghai Jiakai Biological Co.,Ltd. |